Health Ministry Moves to Curb Prescription Drug Ads by Retailers
The Union Health Ministry plans to restrict retailers and wholesalers from advertising Schedule H, H1, and X drugs to prevent self-medication.
In a significant move to prevent the unauthorized promotion of potent medicines, the Union Ministry of Health and Family Welfare has proposed new regulations to tighten the advertising rules for prescription-only drugs. The proposed amendment aims to close a regulatory loophole that currently allows retailers and wholesalers to advertise certain high-risk medicines without the same level of scrutiny applied to manufacturers.
Closing the Regulatory Gap
Under the current legal framework, pharmaceutical manufacturers are strictly prohibited from advertising drugs listed under Schedule H, Schedule H1, and Schedule X without obtaining prior sanction from the Central Government. However, the existing rules did not explicitly extend these restrictions to the entities responsible for the sale and distribution of these drugs.
To fix this, the Ministry has proposed inserting a new sub-rule under Rule 65 of the Drugs Rules, 1945. This amendment would ensure that anyone holding a license to sell, stock, exhibit, or distribute drugs—including both retail pharmacists and wholesale distributors—must also seek Central Government approval before advertising any medicine classified under these sensitive schedules.
Why These Restrictions Matter
The primary objective behind this crackdown is to safeguard public health and reduce the dangerous trend of inappropriate self-medication. The drugs targeted by this amendment include:
- Certain Antibiotics: To combat the growing threat of antibiotic resistance.
- Psychotropic Medicines: Which require strict medical supervision due to their impact on the central nervous system.
- Other Prescription-Only Drugs: Medicines that are unsafe to use without a doctor's direct oversight.
By extending oversight across the entire pharmaceutical supply chain, the government intends to discourage the direct-to-consumer promotion of medicines that are meant to be dispensed only under professional medical guidance.
The Path to Implementation
The proposal follows recommendations made during the 93rd meeting of the Drugs Technical Advisory Board (DTAB) held in February 2026. The board highlighted the urgent need for provisions that govern how drug sale and distribution license holders promote their stock.
The draft amendment was officially notified through Gazette Notification GSR 861(E) on September 28, 2026. The Ministry has now opened a window for public discourse, inviting objections and suggestions from stakeholders and the general public. The Central Government will review all submissions received within the 30-day window before finalizing the new rules.